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1 Drug description 
Generic/Brand name:  
Trabectedin, ET 743 (Yondelis ®) 
Developer/Company:  
Pharma Mar, S.A. (Madrid, Spain) 
Description:  
Trabectedin belongs to the pharmacotherapeutic group of antineoplastic 
agents (ATC code: L01CX01). It was originally derived from the marine 
tunicate Ecteinascidia turbinate and is now produced synthetically [1]. Tra-
bectedin binds to the minor groove of DNA to prevent cancer cells from di-
viding too quickly and therefore slowing down the growth of various types of 
cancer, including sarcoma and ovarian cancer [2]. 
The recommended treatment regimen for patients with ovarian cancer (OC) 
consists of an intravenous infusion of 1.1 mg/m² body surface area trabecte-
din over 3 hours immediately after administration of 30 mg/m² body surface 
area pegylated liposomal doxorubicin (PLD) [3]. 
2 Indication 
Trabectedin is indicated for the treatment of patients (pts) with advanced, 
recurrent/relapsed platinum-sensitive ovarian cancer in combination with 
pegylated liposomal doxorubicin (PLD). 
3 Current regulatory status 
Trabectedin was granted orphan drug designation from the European 
Commission (EC) and the US Food & Drug Administration (FDA) for the 
treatment of soft tissue sarcoma (2001 by EC and 2004 by FDA) and ovarian 
cancer (2003 by EC and 2005 by FDA) [1, 4]. 
Currently, trabectedin is approved by the EMEA for the treatment of pa-
tients with advanced soft tissue sarcoma (STS), after failure of antracyclines 
and ifosfamide or for patients who are unsuitable to receive these agents [5].  
Trabectedin 
(Yondelis ®) 
antineoplastic agent 
recommended dose of 
trabectedin in OC 1.1 
mg/m2 
2nd-line therapy for 
recurrent/relapsed OC 
patients 
orphan drug designation 
in Europe and USA 
approved for the 
treatment of patients 
with STS and OC 
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In September 2009 the Committee for Human Medicinal Products (CHMP) 
of the EMEA advocated the extension of marketing authorisation of trabect-
edin for the treatment of patients with relapsed/recurrent platinum-
sensitive ovarian cancer in combination with pegylated liposomal doxorubi-
cin (PLD) [6], which was then granted marketing authorisation by the 
European Commission in October 2009 [7]. However, the US FDA voted 
14:1 against the approval of trabectedin for the treatment of patients with 
recurrent/relapsed advanced ovarian cancer in July 2009 [8]. Since October 
2009, trabectedin is approved for the treatment of patients with relapsed 
platinum-sensitive ovarian cancer in combination with PLD in the United 
Kingdom [3]. 
4 Burden of disease 
Ovarian cancer is the leading gynaecological type of cancer causing death. 
Every year 13.1 per 100,000 women are diagnosed with ovarian cancer in the 
US [9] and in 2007 8.8 per 100,000 women were diagnosed with ovarian can-
cer in Austria [10]. The median age at diagnosis of ovarian cancer is 63 years 
(out of these women 12% are <45 years, 41.2% are between 45 and 64 years 
and 44.5% are ≥ 65 years at time of diagnosis) [11]. 
Overall, the annual age-adjusted death rate per year of patients suffering 
from ovarian cancer was 8.8 per 100,000 women in the US and 5.5 per 
100,000 women in Austria in 2007, respectively [9]. 
Signs and symptoms of ovarian cancer occur very late, therefore over 75% of 
ovarian cancer patients suffer from advanced stage III or stage IV disease at 
time of diagnosis [12-13].  
After cytoreductive surgery and platinum-based adjuvant chemotherapy in 
combination with paclitaxel several factors (disease stage, age, etc.) play an 
essential role in disease relapse. 
Patients with stage I/II disease show a relapse rate of 10-20%, whereas pa-
tients at advanced stage III-IV ovarian cancer relapses in 60-85% of cases 
[14]. 
According to Statistik Austria the incidence of ovarian cancer and disease 
related death rate continuously declined over the past decades (e.g., reduc-
tion of disease related death rate of 11% over the last 10 years) [10, 15]. 
Age is also considered as a risk factor for relapse and survival. While women 
under 40 years have a 5-year survival rate of 65%, only 20% of ovarian can-
cer patients older than 40 years are alive five years after diagnosis [14]. 
Besides age and nulliparity, risk factors for developing the disease are early 
age of menarche, late age of menopause and family history of ovarian, breast 
or endometrial (uterine) cancer [16], An identifiable genetic predisposition 
(e.g. BRCA1/BRCA2) is present in only 10% - to 15%  of patients [17]. 
Different systems are available to classify cancer stages. The most commonly 
used for staging ovarian cancer are the FIGO (Fédération International de 
Gynécologie et d’Obstrétique) and the TNM (tumour, node, metastasis) stag-
ing system. The five general stages of the FIGO system are: 
CHMP recommended 
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for OC 
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for OC 
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 Stage 0: “Pre-cancer” or carcinoma in situ. 
 Stage I: Tumour limited to ovaries 
 Stage II: Tumour involves one or both ovaries with pelvic extension 
and/or implants 
 Stage III: Tumour involves one or both ovaries with microscopically 
confirmed peritoneal metastasis outside the pelvis 
 Stage IV: Patient shows distant metastasis [18] 
5 Current treatment 
The generally recommended first-line therapeutic approach is cytoreductive 
surgery followed by systemic chemotherapy with a platinum agent plus a 
taxane (mostly paclitaxel) for patients with poor prognostic factors like ad-
vanced stage of disease [12, 14]. Only patients with early stage ovarian can-
cer and good prognostic factors are not offered adjuvant chemotherapy [12, 
14]. 
Unlike first-line therapy of ovarian cancer no standard of care has been es-
tablished yet for recurrent ovarian cancer [1]. Choice of second-line therapy 
does not primarily depend on risk factors such as age or stage of disease, but 
the duration of response of each patient to first-line therapy helps in select-
ing a suitable second-line therapy [12, 14]. Generally, recurrent ovarian can-
cer patients are classified as: 
 Platinum-sensitive: progression-free survival (PFS) >6 months af-
ter initial platinum-based chemotherapy. 
 Platinum-resistant: patients who relapse within 6 months following 
initial platinum-based chemotherapy. 
 Platinum-refractory: patients whose disease progresses while on 
platinum-containing therapy [12, 19]. 
Besides platinum agents (cisplatin and carboplatin) the following drugs are 
active in ovarian cancer patients: paclitaxel, docetaxel, oral etoposide, pegy-
lated liposomal doxorubicin, topotecan, gemcitabine, vinorelbine, ifos-
famide, leucovorin-modulated 5-fluorouracil, bevacizumab and tamoxifen 
[1, 14, 18]. 
Recommended second-line treatment for  
 Platinum-sensitive ovarian cancer patients: data of phase II/III tri-
als strongly support the retreatment with platinum-based chemo-
therapy regimens (cisplatin or carboplatin) in combination with 
paclitaxel or docetaxel (60% response rate; 25% complete re-
sponse). As patients have already responded once to systemic che-
motherapy with platinum-agents and taxanes they are likely to do 
so again [14]. 
 
 
1st-line OC therapy 
no standard 2nd-line OC 
therapy is established 
yet 
choice of 2nd-line 
therapy according to 
response to 1st-line 
platinum-containing 
therapy 
several active agents in 
OC 
2nd-line therapy for 
platinum-sensitive and 
platinum-resistant 
refractory/relapsed OC 
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 Platinum-recurrent/resistant ovarian cancer patients: although 
combination regimens with non-cross resistant agents are associ-
ated with higher objective response rates and a two to three months 
improvement in PFS, they were also more toxic in clinical trials. 
Therefore single agent therapy is standard of care for platinum-
resistant/refractory ovarian cancer patients [14]. 
The most suitable single agents for second-line recurrent ovarian cancer are 
pegylated liposomal doxorubicin, topotecan or gemcitabine which have 
shown 16-40% response rates [12]. 
6 Evidence 
Based on a limited literature search in several databases (PubMed, CRD and 
Embase) and on an additional hand search, one phase III trial and three 
phase II trials evaluating the efficacy of trabectedin in relapsed ovarian can-
cer were identified. Within these 4 trials 985 patients suffering from recur-
rent advanced ovarian cancer after initial platinum-based chemotherapy 
were treated with trabectedin or trabectedin in combination with PLD. 
Toxicitiy profiles were generally regarded as clinically manageable. The 
most common grade 3/4 adverse events were neutropenia and elevations of 
transaminases [8]. The most frequently AEs were nausea, vomiting and fa-
tigue of grade 1 or 2. 
All authors concluded that trabectedin as a single agent or in combination 
with PLD is more effective in platinum-sensitive patients than in platinum-
refractory patients. 
6.1 Efficacy and safety - Phase III studies 
Table 1: Efficacy and safety of Phase III trials 
Reference  OVA-301 trial, ongoing (NCT00113607 until May 2011), abstract LBA4 (ESMO 
2008) [20] 
Further information: 
Platinum-Sensitive Recurrent Ovarian Cancer (non-platinum Doublets) [21] 
FDA – Background information for Oncologic Drugs Advisory Committee Meeting 
July 15, 2009 [8] 
Sponsor Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 
 Country 124 centres in 21 countries in USA, Europe, Asia and South America [13] 
Design Open-label, multi-centre, randomized trial, radiologists were blinded to treatment 
and clinical data 
Participants characteristics 672 pts (I: 337, C: 335) 
Median age: I: 56 years, C: 58 years 
Platinum-sensitive: I: 65%, C: 63% 
Platinum-resistant: I: 35%, C: 37% 
ECOG PS1 O/1/2 (%): I: 68/29/3, C:  57/39/3 
Treatments I(ntervention): pegylated liposomal doxorubicin (PLD) 30 mg/m2 90-min infusion 
followed by trabectedin 1.1 mg/m2 3-hr infusion every 3 weeks 
C(ontrol): PLD 50 mg/m2 90-min infusion once in 4 weeks 
1 phase III trial, 
3 phase II trials 
adverse events: 
neutropenia, elevations 
of transaminases, 
nausea, vomiting, 
fatigue 
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In-/exclusion criteria Inclusion criteria: 
histologically proven epithelial ovarian cancer, epithelial fallopian tube cancer, or 
primary peritoneal cancer. 
Prior treatment with only 1 platinum based chemotherapy regimen. 
ECOG PS status ≤ 2. 
Progression > 6 months after start of initial chemotherapy 
Exclusion criteria: 
More than 1 prior chemotherapy regimen. 
Progression within 6 months after starting initial chemotherapy. 
Prior exposure to anthracyclines. 
Follow-up Follow-up, not recruiting 
Outcomes Primary: progression free survival (PFS) based on independent radiology review 
(IR) by RECIST 
Secondary: response rate (RR) by IR, interim survival at 300 deaths revealed (OS), 
quality of life (QoL) 
Key results  by predetermined 
clinical cut-off date (15 May 
2008; study start: April 2005) 
Primary: 
Median PFS (no. censored: 256) for I: 7.3 months (95% CI 5.9-7.9) vs C 5.8 months 
(95% CI 5.5-7.1). HR= 0.79 (95% CI 0.65 to 0.96), p=0.019,  
for patients with a platinum-free interval > 6 months (PFI >6 m): I 9.2 months 
(95% CI 7.4 to 11.1 months) C 7.5 months (95% CI 7.0 to 9.2 months), HR= 0.73, 
p=0.017 
 
Secondary: 
RR: I 28% vs. C 19% (p=0.008) 
for patients with PFI >6 m RR was I 35% vs. C 23% (p=0.0042) 
OS (interim analysis, no. censored: 372): I 20.5 (18.7-24.2) months vs. C 19.4 (17.3-
21.7) months, HR= 0.85 (95% CI 0.67-1.16) p=0.15 
Deaths: 300 at time of the PFS cut-off date (55% censored data; I 145 and C 155 
deaths) 
QoL: no significant differences (EORTC-QLQ C30, OV 28, EQ-5D) 
Adverse effects Treatment discontinuation due to treatment related adverse events. I 16% vs. C 
10%. 
Grade 3/4 adverse events: 
- Haematological laboratory abnormalities: neutrophils I 72% vs. C 30%, WBC I 
63% vs. C 20%, platelets I 23% vs. C 4% 
- Biochemistry (laboratory abnormalities): ALT2 increase I 51% vs. C 2% 
- Selected AEs: neutropenia I: 63% vs. C: 22%, febrile neutropenia I 8% vs. C 3%, 
hand-foot syndrome I 4% vs. C 19%, mucositis/stomatitis I 3% vs. C 12%, fatigue I 
9% vs. C 6%, vomiting I 13% vs. C 4 %, nausea I 10% vs. C 4% 
Commentary The data presented in this table are an interim analysis of the OVA-301 phase III 
trial. Final data collection is estimated for May 2011 (see: www.clinicaltrials.gov 
NCT00113607). 
This interim analysis shows that the combination of pegylated liposomal doxoru-
bicin and trabectedin is superior regarding the surrogates PFS and RR in women 
with advanced ovarian cancer compared to pegylated liposomal doxorubicin 
alone. 
 
___________________________________________________ 
1 ECOG PS – Eastern Cooperative Oncology Group performance status 
2 ALT - Alaninaminotransferase 
 
The data presented in Table 1 are an interim analysis of an ongoing phase 
III trial evaluating the efficacy and safety of trabectedin in combination with 
PLD in patients with recurrent, advanced ovarian cancer. 
Results from 
interim analysis 
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Patients included in this trial progressed after initial response to first-line 
therapy and were randomized to two treatment arms: pegylated liposomal 
doxorubicin in combination with trabectedin (PLD+T) or PLD alone. The 
demographic characteristics between the study arms were well balanced. A 
subgroup analysis showed that PLD+T was more effective regarding PFS 
than PLD alone in platinum-sensitive (platinum free interval (PFI) > 6 
months) patients I: 9.2 months (95% CI 7.4 to 11.1 months) vs. C: 7.5 
months (95% CI 7.0 to 9.2 months). The response rate for platinum-sensitive 
patients was 35% vs. 23% (p=0.0042) for PLD+T vs. PLD only by IR and 
47% vs. 33% (p=0.0022) by investigator for PLD+T vs. PLD alone. 
Additional to the data presented in the table above, two abstracts from the 
ASCO annual meeting 2009 were found evaluating the health related quality 
of life (QoL) and patient reported outcomes (PRO) [22] in the OVA-301 trial 
and the correlation of CA-125 and RECIST evaluation to determine re-
sponse rates [23] in recurrent ovarian cancer. 
The instruments used to assess QoL/PRO were EORTC-QLQ C30, OV28 
and EQ-5D, which were completed by patients at screening on day 1 and at 
the end-of-treatment visit of every other treatment cycle (starting with cycle 
1). Mixed effects models showed no significant differences between the treat-
ment arms for the pre-specified scales (global health status/QoL, fatigue, 
pain, subscales from QLQ C30, abdominal pain/GI symptoms scale from 
OV28) [22]. Though, treatment related adverse events like neutropenia and 
elevated ALT level were more frequent in the intervention arm than in the 
control arm. 
Dose reduction of PLD of 20mg/m² in the intervention arm compared to the 
control arm led to a decrease in PLD-related AEs (e.g. hand-foot syndrome I 
24% vs. C 54%, stomatitis I 20%, C 33%). However, general toxicity assess-
ment showed that AEs were more frequent and more severe in the trabec-
tein+PLD arm (e.g. hospitalization due to AEs I 36%, C 27%, discontinua-
tion due to AEs I 69 (of 325) patients, C 39 (of 322) patients.) 
6.2 Efficacy and safety - further studies 
Three phase II trials were identified [12, 24-25]. Two of these phase II trials 
evaluated the overall response rate of platinum-sensitive vs. platinum-
resistant/refractory patients [12, 24] and one phase II trial evaluated the op-
timal dose of trabectedin in platinum-sensitive patients [25]. 
The studies included demonstrated the effectiveness of trabectedin as a sin-
gle agent in the platinum-sensitive patient population with respect to objec-
tive response rate (ORR). The table below shows that trabectedin is more ef-
fective in treating women with platinum-sensitive recurrent ovarian cancer 
than in platinum-refractory ovarian cancer patients. 
Sessa et al. [24] conducted a phase II study to determine the efficacy and 
toxicity of trabectedin in treating patients with histologic or cytologic con-
firmed epithelial ovarian cancer who relapsed after fist-line treatment with 
platinum-containing regimens with taxanes and/or other drugs. 59 patients 
from 4 institutions were stratified according to their response to prior che-
motherapy as either platinum-sensitive (n=29; progression free interval ≥ 
6months between the last chemotherapy cycle and documentation of re-
trabectedin more 
effective in platinum-
sensitive OC patients 
regarding the surrogates 
PFS, RR, OS 
assessment of QoL  
& PRO 
no difference in QoL 
AEs (grade 3, 4): more 
frequent & severe in 
combination arm 
dose-finding and 
determination of 
response rates 
59 relapsed/refractory 
OC patients included 
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lapse) or platinum-resistant (n=30; progression-free interval of less than 6 
months or progressive disease while receiving platinum-based chemother-
apy). 
After start of therapy, the original dose had to be reduced once in 29% and 
twice in 13% of patients due to toxicity. Trabectedin was administered as a 
3-hour infusion using an ambulatory infusion pump through a separate line 
every 3 weeks. Patients received a median of 4 treatment cycles (range 1-13). 
5 patients were excluded early from the trial because of severe toxicity.  
Efficacy data are shown in Table 2, suggesting that trabectedin is more effec-
tive in platinum-sensitive patients compared to platinum-
resistant/refractory patients. 
The most common toxicity was a severe but reversible increase of liver func-
tion tests. Grade 3/4 toxicities reported in this phase II trial were neutro-
penia (41%), thrombocytopenia (7.5%), asthenia (7% - only grade 3) and 
nausea and vomiting (5% - only grade 3). Neurotoxicity and alopecia were 
not observed. Two patients discontinued treatment, because of lack of hema-
tologic recovery and none because of liver toxicity. 
Krasner et al. (2007) [12] conducted a multicenter phase II trial to deter-
mine the ORR in patients with platinum-sensitive or –resistant/recurrent 
ovarian cancer when treated with trabectedin. Patients (n=147) were eligi-
ble to participate in the study if they demonstrated measurable relapsed ad-
vanced OC and if they had not receive more than two prior platinum-
containing regimens. Depending on the treatment-free interval (TFI) pa-
tients were assigned to the study cohort, being either platinum-sensitive 
(n=66) or platinum resistant (n=81). Platinum sensitive and platinum-
resistant/refractory patients received a median number of 4 and 2 cycles of 
trabectedin with a median treatment duration of 18.6 and 8.9 weeks, respec-
tively. 
Major reasons for cycle delays, dose withholds and dose reductions were 
liver transaminase elevations and myelosuppression which were more fre-
quent in the platinum-sensitive than in the platinum- resistant/refractory 
cohort. 31.8% of the platinum-sensitive and 10.1% of the platinum-
resistant/refractory cohort remained on therapy longer than 6 months.  
Response rates were generally better within the platinum-sensitive com-
pared to the platinum-resistant cohort, supporting the findings of Sessa et 
al. 2005 (see Table 2).  
Toxicity evaluation was presented for all 147 evaluable patients of whom 146 
patients reported at least one laboratory abnormality.The most common 
laboratory grade 3 and grade 4 adverse events were neutropenia (7%/1%), 
elevated ALT (12%/0%), hyponatraemia (8%/1%) and hypoalbuminemia 
(7%/0%). Other adverse events  (grades 1-4) were nausea (69%), vomiting 
(47%), fatigue (60%) and constipation (33%). 7% of patients discontinued 
the therapy due to drug-related AEs and one of the 5 death cases in the trial 
was caused by drug-related AEs [12]. 
DelCampo et al. [25] conducted a randomized, open-label phase II trial to 
explore the benefit-risk ratio and the optimal treatment regimen with tra-
bectedin in patients with platinum-sensitive, relapsed advanced ovarian 
cancer. Patients with histological proven progressive ovarian adenocarci-
noma, with a platinum-sensitive disease (defined as ≥ 6 months platinum-
free interval) and ECOG PS 0 or 1 were eligible. The two study cohorts re-
dose reduction due to 
toxicities 
grade 3/4 toxicities: 
neutropenia, 
thrombocytopenia, 
asthenia, nausea, 
vomiting 
147 resistant/recurrent 
OC patients included 
median cycles of 
therapy: platinum-
sensitive: 4 
reasons for dose 
withholds or reductions 
AEs: neutrophils, 
elevated ALT, 
hyponatraemia, 
hypoalbiminemia, 
neutropenia, nausea, 
vomiting, fatigue, 
constipation 
death caused by drug-
related AEs 
determination of 
benefit-risk ratio in 107 
relapsed OC patients 
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ceived either 1.5 mg/m² over 24 hours (arm A, n=54) or 1.3 mg/m² over 3 
hours (arm B, n=53) of trabectedin administered as an intravenous infusion 
through a central line. 
Primary study endpoint was ORR and secondary endpoints included dura-
tion of response and time to progression (TTP). 
A median of 5 (range 1-19) and 6 (1-29) cycles per patient were administered 
in arm A and B, respectively. Response rates and stable disease are pre-
sented in Table 2. Median time to progression was 6.2 months (95% CI 5.3-
8.6) in arm A and 6.8 months (95% CI 4.6-7.4) in arm B. 
The most common observed drug related AEs were nausea, vomiting and fa-
tigue, most of them being grade 2 or 3. Grade 4 fatigue, asthenia and dysp-
noea were reported each in at least one patient. The most common hema-
tologic AEs (grade 3/4) were grade 4 neutropenia 36% and 26%, and grade 3 
leukopenia 30% and 26% for arm A and arm B, respectively. However, se-
vere clinical consequences of neutropenia were uncommon and febrile neu-
tropenia occurred in one patient in arm A and in 4 patients in arm B. The 
most frequent biochemical abnormalities were increased ALT and AST. 
During the study, 27 patients died. Two of them were treatment related and 
the others were caused by disease progression. 
Finally, the authors concluded that trabectedin administered as 1.5 mg/m² 
over 24 h and 1.3mg/m² over 3 h is effective in patients with platinum-
sensitive relapsed, advanced ovarian cancer and shows a clinically tolerable 
toxicity profile. 
Table 2: Objective response rate, partial response and stable disease 
 Platinum-sensitive Platinum-resistant/refractory 
 ORR in %  CR in % PR in % SD in % ORR in %  CR in % PR in % SD in % 
Krasner et al. 
2007 [12] 
29 (95% CI 
18.2-41.9) 6 23 35 
6.3 (95% 
CI 2.1-14.2) 0 6 46 
Sessa et al. 
2005 [24] 
43 (95% CI 
23-65) 4 39 39 n.e. 0 7 29 
Del Campo et 
al. 2009 [25] 
A: 38.9 (95% 
CI 25.9-53.1) 
B: 35.8 (95% 
CI 23.1-50.2) 
A: 11.1 
B: 11.3 
n.e. 
A: 38.9 
B: 47.2 
n.e. n.e. n.e. n.e. 
ORR – overall response rate, CR – complete response, SD – stable disease, n.e. – not 
evaluable, n.r. – not reported 
A: 24-h 1.5 mg/m² q3wk 
B: 3-h 1.3 mg/m² q3wk 
 
The data presented above suggest that trabectedin is more effective in plati-
num-sensitive than in platinum-refractory patients regarding the surrogates 
RR and PFS.  
median number of 
treatment cycles: 5-6 
AEs: nausea, vomiting, 
fatigue, asthenia, 
dyspnoea, neutropenia, 
leukopenia 
two treatment related 
deaths 
efficacy regarding RR & 
PFS 
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7 Estimated costs 
Price estimate for one vial containing 0.25 mg of trabectedin is € 530.- and 
for 1 mg € 1994.- (pharmacy retail price). One vial containing 25 ml PLD 
(Caelyx ®) 2 mg/ml costs € 1,148.65 [26]. 
The dosing regimen used in the included OVA-301 phase III trial was 1.1 
mg/m² trabectedin and 30 mg/m² PLD. Thus, assuming an average body 
surface area of 1.7 m² would result in 1.87 mg trabectedin (i.e. 2 vials) for 
one cycle, and would cost € 3,988.- (pharmacy retail price). Additionally, on 
average 50 mg PLD are needed, corresponding to one 25 ml vial. Hence, the 
overall costs for one treatment cycle with PLD and trabectedin is € 6,285.3. 
As no long term data for the use of trabectedin in the treatment of recurrent 
platinum-sensitive ovarian cancer is available, we based the calculation of 
treatment costs on the median duration of treatment presented in the in-
terim data analysis of the OVA-301 trial [22]. 
As the median treatment duration of trabectedin + PLD was 6 cycles (range 
1-22) with a median treatment duration of 20.4 weeks we propose here the 
calculation of therapy costs per patient for 6 cycles of therapy which are € 
37,711.8 [8]. 
8 Ongoing research 
There are several phase I, II and III trials evaluating the effectiveness of tra-
bectedin in different kinds of cancer (prostate cancer, solid tumours, sarco-
mas, breast cancer) listed at ClinicalTrial.gov.  
Besides the Phase III trial NCT00113607 evaluating the efficacy and safety 
of trabectedin and pegylated liposomal doxorubicin (PLD) or PLD alone in 
patients with advanced, relapsed ovarian cancer, one further phase II trial 
has to be mentioned in this report. 
The purpose of NCT00569673 is to study the side effects and docetaxel and 
trabectedin in combination with either G-CSF or pegfilgrastim for the treat-
ment of patients with recurrent or persistent ovarian epithelial cancer, fallo-
pian tube cancer or primary peritoneal cavity cancer. 
9 Commentary - English 
Both, phase II and phase III trials presented in chapter 6 showed that tra-
bectedin is effective regarding the surrogate outcome response rate (RR) in 
patients with relapsed ovarian cancer. Subgroup analyses demonstrated that 
platinum-sensitive patients had higher objective RR compared to platinum-
resistant/refractory ovarian cancer patients (see Table 2). 
Treatment costs for one 
cycle: 6,300.- 
6 cycles: 37,700.- 
median number of 
cycles PLD+trabectedin 
was 6 
several phase I, II & III 
trials are evaluating the 
efficacy of trabectedin 
trabectedin more 
effective in platinum-
sensitive pts than in 
platinum-resistant pts 
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The findings of phase II trials are supported by the results the OVA-301 
phase III trial. This trial compared trabectedin + PLD with PLD alone 
which is a well established therapy and hence an appropriate control. It was 
shown that the RR by independent radiology review is 28% vs. 19% in fa-
vour of the trabectedin + PLD arm compared to the PLD alone arm. RR for 
the platinum-sensitive subgroup analysis was 35% vs. 23% [20]. In an analy-
sis three years after the study’s start, interim OS was slightly improved by 
1.1 months when trabectedin was added to PLD [8].  
Further, the OVA-301 trial showed that the combination of trabectedin with 
PLD leads to a gain of, overall, 1.5 months of median PFS. Within the plati-
num-sensitive subgroup a gain of PFS of 1.7 months compared to PLD alone 
was reached. Grade 3/4 adverse events were more frequent in the interven-
tion group, resulting in treatment discontinuation due to treatment related 
AEs in 16% of the intervention group and in 10% of the control group [8]. 
According to a presentation at the 2009 ASCO annual meeting, the addition 
of trabectedin neither led to a decline nor to an improvement in quality of 
life for patients treated with the PLD + trabectedin combination [22].  
Considering the results of the pivotal OVA-301 trial and several phase II tri-
als, EMEA and FDA issued different opinions regarding benefit-and-risk as-
sessment which has consequently led to deviating decisions for marketing 
authorisation of trabectedin for the treatment of relapsed platinum-sensitive 
ovarian cancer. 
The EMEA acknowledged that, despite favourable results for PFS, the mag-
nitude of the observed effect of 1.5 months is not impressive but within an 
expected range for this type of cancer. Supported by an ad-hoc interim 
analysis, the benefit-risk ratio was finally considered as being positive for 
patients with platinum-sensitive ovarian cancer, by reasons that the combi-
nation of trabectedin with PLD showed increased efficacy without worsen-
ing clinical safety substantially and without compromising quality of life. 
However, due to other available treatment options for patients with plati-
num-sensitive tumours (foremost platinum based regimens) the lack of di-
rect head-to-head comparisons between these treatment regimens and hence 
the demonstration of their relative efficacy was criticised [5].  
On the other hand, a vote conducted by the FDA led to the rejection of the 
application of Yondelis® by the Oncologic Drug Advisory Group, although, 
study results show a reduction in the risk of progression similarly to that of 
other drug combinations already approved [8]. Concerns included whether 
toxicities were outweighed by the established clinical benefit without dem-
onstration of an increased overall survival. Hence, the FDA, like the EMEA, 
calls for mature OS data to support the prolonged surrogate PFS [27]. 
Thus, considering the prolongation of PFS of 1.7 months in platinum-
sensitive OC patients, neither decline nor amelioration of quality of life, the 
additional treatment costs and the frequency and severity of adverse events, 
the net benefit for affected patients has to be carefully balanced. 
tabectedin shows 
efficacy regarding the 
increased response rate 
OS: 1.1 months 
slight, yet statistical 
significant improvement 
regarding PFS (6 weeks) 
when trabectedin added 
to PLD 
comparable quality of 
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prolongation of PFS not 
impressive 
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Sowohl die Phase II als auch die Phase III Studie, die in Kapitel 6 dieses As-
sessments dargestellt wurden, zeigen die Wirksamkeit von Trabectedin bei 
rezidiviertem Ovarialkarzinom anhand verbesserter Ansprechraten. In Sub-
gruppen-Analysen wird ersichtlich, dass die Wirksamkeit in Patientinnen, 
welche als platinsensitiv eingestuft wurden, höher ist als bei nicht-
platinsensitiven Patientinnen (vgl. Tabelle 2). 
Die Resultate der Phase II Studien konnten durch die Ergebnisse der OVA-
301 Phase III Studie bekräftigt werden. Diese Studie verglich die Kombina-
tion von Trabectedin und PLD versus PLD als Monotherapie. PLD gilt als 
gut etablierte Monotherapie und stellt daher eine adäquate Kontrolle dar. 
Bei der unabhängigen radiologischen Untersuchung konnte zu Gunsten des 
Kombinationsarms eine Ansprechrate (RR) von 28% vs. 19% beim PLD-
Arm gezeigt werden. RR für die platinsensitive Subgruppenanalyse war 35% 
im Interventionsarm vs. 23% im Kontrollarm [20]. Drei Jahre nach Studien-
beginn zeigte eine Analyse ein leicht verbessertes Gesamtüberleben von 1,1 
Monate beim Kombinationsarm [8]. 
Weiters zeigt die OVA-301 Studie, dass die Kombination von Trabectedin 
mit PLD zu einem Gewinn von 1,5 Monaten an durchschnittlichem progres-
sionsfreiem Überleben (PFS) führt. Innerhalb der platinsensitiven Unter-
gruppe konnte ein Zugewinn an durchschnittlichem PFS von 1,7 Monaten 
erreicht werden. Grad 3/4 Nebenwirkungen traten häufiger in der Interven-
tionsgruppe auf. Bei 16% der Interventionsgruppe und bei 10% der Patien-
tinnen in der Kontrollgruppe führten behandlungsbezogene Nebenwirkun-
gen zum Therapieabbruch [8]. 
Die 2009 beim jährlichen ASCO-Meeting präsentierten Daten zur Lebens-
qualitätsauswertung der OVA-301 zeigten keinen Unterschied in der Le-
bensqualität (QoL) zwischen den beiden Vergleichsgruppen [22]. 
Hinsichtlich des Nutzen-Risiko Verhältnisses der Trabectedin-
Kombinationstherapie im Vergleich zu anderen Therapieoptionen urteilten 
EMEA und FDA unterschiedlich, was schlussendlich auch zu konträren 
Entscheidungen bei der Marktzulassung von Trabectedin beim rezidivier-
tem platinsensitiven Ovarialkarzinom führte. 
Die EMEA führte zwar an, dass trotz der positiven PFS Resultate, das Aus-
maß des beobachteten Effekts nicht beeindruckend ist, allerdings in einem 
für diese Krebsart erwarteten Bereich liegt. Die Nutzen-Risiken Abwägung 
wurde nach einer Ad-hoc-Zwischenanalyse schlussendlich als positiv für Pa-
tientinnen mit rezidiviertem platinsensitivem Ovarialkarzinom eingestuft. 
Grund dafür war, dass die Kombination von Trabectedin mit PLD zu erhöh-
ter klinischer Wirksamkeit, ohne substantieller Verschlechterung der klini-
schen Sicherheit und ohne Beeinträchtigung der Lebensqualität führte. 
Trotzdem wurde aufgrund von anderen bereits verfügbaren Therapieoptio-
nen für Patientinnen mit Ovarialkarzinom (hauptsächlich platin-basierte 
Therapien) das Fehlen von direkten Head-to-head Studien von diesen Be-
handlungsoptionen und dadurch auch der fehlende Nachweis für deren rela-
tive Wirksamkeit kritisiert [5]. 
erho¨hte Wirksamkeit 
von Trabectedin in 
platinsensitivem OC 
RR im Kombinationsarm 
ho¨her als im 
Vergleichsarm 
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Auf der anderen Seite führte eine Abstimmung der FDA zu einer Ableh-
nung der Marktzulassung von Yondelis ®, obwohl bei der OVA-301 Studie 
eine ähnliche Risikoreduktion des progressionsfreien Überlebens wie bei 
anderen, bereits zugelassenen Therapieoptionen nachgewiesen werden 
konnte [8]. Es wurde in Frage gestellt, ob die Toxizität der Therapie durch 
den erreichten klinischen Nutzen, ohne Nachweis eines verlängerten Ge-
samtüberlebens, ausgeglichen werden kann. Infolgedessen fordern sowohl 
die FDA, als auch die EMEA die Untermauerung des Surrogats PFS durch 
ausgereifte OS-Daten [27]. 
Berücksichtigt man demnach den Gewinn von 1,7 Monaten an PFS, die 
gleichbleibende Lebensqualität, zusätzliche Behandlungskosten und die zu-
sätzlichen Nebenwirkungen, ist der Netto-Nutzen von Trabectedin mit PLD 
für Patientinnen mit rezidiviertem Ovarialkarzinom sorgfältig abzuwägen. 
 
FDA: Ablehnung des 
Antrags auf 
Maktzulassung 
 
forderung von 
ausgereiften OS-Daten 
Netto-Nutzen muss 
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